StockNews.com assumed coverage on shares of Oragenics (NYSE:OGEN – Free Report) in a report published on Wednesday. The brokerage issued a sell rating on the stock.
Oragenics Stock Down 8.7 %
NYSE OGEN opened at $0.42 on Wednesday. Oragenics has a 52 week low of $0.40 and a 52 week high of $7.74. The business has a 50 day moving average price of $0.94 and a 200-day moving average price of $1.27. The company has a market cap of $2.34 million, a price-to-earnings ratio of -0.05 and a beta of 0.50.
Oragenics (NYSE:OGEN – Get Free Report) last announced its quarterly earnings results on Friday, August 9th. The company reported ($0.51) EPS for the quarter.
Hedge Funds Weigh In On Oragenics
About Oragenics
Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.
Read More
- Five stocks we like better than Oragenics
- Stock Analyst Ratings and Canadian Analyst Ratings
- Should You Invest in Treasury Bills?
- How to Invest in Insurance Companies: A GuideĀ
- Analysts Think There’s Still Time to Get in on Edgewise, Up 332%
- How to Invest in Tech StocksĀ and Top Tech Stocks to Consider
- 3 Stocks Raising Dividends 4X Higher Than Inflation
Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.